The efficacy and @entity137 of combined @entity13750 with XXXX as a first-line chemotherapy for advanced @entity1721 .

@entity1 @entity137 @entity66 @entity1311 @entity1721 @entity1209 @entity1207 @entity418 @entity1282 @entity13750 @entity1210
BACKGROUND: To assess the efficacy and @entity137 of combined @entity13750 with @entity1311 (LP) as a first line chemotherapy in @entity418 . METHODS: The clinical data of 45 @entity1 with @entity1721 treated initially with @entity13750 - @entity1311 chemotherapy were collected and reviewed retrospectively. The overall response, treatment @entity137 and @entity1282 relief were analyzed with SPSS software. RESULTS: The overall response rate was 42.2%, with 1 @entity1 (2.2%) showing complete remission, 18 @entity1 (40.0%) with partial remission, 19 (42.2%) with @entity66 ( @entity66 ), and 7 (15.6%) with progressive disease, respectively. The most common hematological @entity137 was @entity1210 with grade 0, I, II, III and IV in 16 (35.6%), 10 (22.2%), 11 (24.4%), 7 (15.6%), and 1 @entity1 (2.2%), respectively. Thirty-seven @entity1 (82.2%) experienced @entity1209 without grade III-IV instances occurring. Four @entity1 (8.9%) experienced grade I hepatotoxicity. No nephrotoxicity was observed. Five in thirteen @entity1 treated with concurrent chemoradiotherapy (CRT) suffered severe @entity1207 . The @entity1282 resolved or improved in 32 @entity1 (71%). CONCLUSIONS: @entity13750 - @entity1311 showed a significant antitumor effect to squamous @entity418 with manageable @entity137 . Limitation of the surveillance time and the retrospective nature, the effect that based on these data formal prospective trials appear warranted and are needed prior to routine first line use of this regimen.
